Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

233 trials with published results (14%)

Research Maturity

1075 completed trials (63% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.4%

110 terminated out of 1716 trials

Success Rate

90.7%

+4.2% vs benchmark

Late-Stage Pipeline

17%

300 trials in Phase 3/4

Results Transparency

22%

233 of 1075 completed with results

Key Signals

233 with results91% success110 terminated

Data Visualizations

Phase Distribution

1,254Total
Not Applicable (680)
Early P 1 (15)
P 1 (99)
P 2 (160)
P 3 (166)
P 4 (134)

Trial Status

Completed1,075
Unknown299
Terminated110
Recruiting103
Withdrawn57
Active Not Recruiting35

Trial Success Rate

90.7%

Benchmark: 86.5%

Based on 1075 completed trials

Clinical Trials (1716)

Showing 20 of 20 trials
NCT07053423Phase 4RecruitingPrimary

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

NCT01273259Phase 2CompletedPrimary

Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults (DHEA-HTAP)

NCT07512687Not ApplicableRecruiting

Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia

NCT00581087Phase 3CompletedPrimary

Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults

NCT06981078Phase 2Active Not RecruitingPrimary

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT07566195Phase 3RecruitingPrimary

Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations

NCT01692444Not ApplicableCompletedPrimary

Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease

NCT01196832Not ApplicableCompletedPrimary

Role of Fibrocytes in Chronic Obstructive Pulmonary Disease

NCT07633314Phase 2Not Yet RecruitingPrimary

A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease

NCT07349524Phase 2RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease

NCT05399056Not ApplicableRecruitingPrimary

Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling

NCT04231760Phase 1Not Yet RecruitingPrimary

The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD

NCT05061368Phase 2RecruitingPrimary

Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD

NCT04236726RecruitingPrimary

Investigating Health Related Quality of Life in Patients With Chronic Respiratory Failure

NCT06603246Phase 1Recruiting

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

NCT05237505Phase 2Recruiting

The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)

NCT05878769Phase 3RecruitingPrimary

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT07073950Phase 4RecruitingPrimary

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

NCT05984680CompletedPrimary

COPD Care Pathway Among Patients With Cancer

NCT07016412Phase 2RecruitingPrimary

A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

Scroll to load more

Research Network

Activity Timeline